# Human Vaccines Market > Human Vaccines Market Research Report By Vaccine Type (Inactivated, Live Attenuated, Subunit, Recombinant, Toxoid), By Application (Preventive Vaccines, Therapeutic Vaccines, Travel Vaccines, Influenza Vaccines), By Administration Route (Intramuscular, Subcutaneous, Oral, Intradermal), By Target Diseases (Infectious Diseases, Oncological Diseases, Autoimmune Diseases) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) -Forecast to 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 5.72% - **2024:** $ 666.04 Million - **2025:** $ 704.14 Million - **2035:** $ 1,228.11 Million - **Key Players:** Pfizer (US), Moderna (US), Johnson & Johnson (US), Sanofi (FR), GlaxoSmithKline (GB), Merck & Co. (US), AstraZeneca (GB), Novartis (CH), Bayer (DE) **Report ID:** MRFR/Pharma/1984-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/human-vaccines-market-2671 --- ## Market Summary As per MRFR analysis, the Human Vaccines Market Size was estimated at 666.04 USD Million in 2024. The Human Vaccines industry is projected to grow from 704.14 in 2025 to 1228.11 by 2035, exhibiting a compound annual growth rate (CAGR) of 5.72% during the forecast period 2025 - 2035. ## Market Drivers ### Increasing Global Vaccination Coverage The Global Human Vaccines Market Industry is experiencing growth due to the increasing emphasis on vaccination coverage across various populations. Governments worldwide are implementing policies aimed at enhancing immunization rates, particularly in developing regions. For instance, initiatives by the World Health Organization focus on achieving universal vaccination coverage, which is projected to significantly impact market dynamics. As of 2024, the market is valued at approximately 48.2 USD Billion, reflecting the importance of vaccination in public health strategies. This trend is expected to continue, with a projected market value of 78.5 USD Billion by 2035, indicating a sustained commitment to improving global health outcomes. ## Future Outlook The Human Vaccines Market is projected to grow at a 5.72% CAGR from 2025 to 2035, driven by technological advancements, increasing vaccination awareness, and expanding healthcare access. **New opportunities:** - Development of personalized vaccines targeting specific demographics. - Expansion of telehealth platforms for vaccine consultations. - Investment in cold chain logistics for vaccine distribution efficiency. By 2035, the Human Vaccines Market is expected to be robust, driven by innovation and strategic investments. ## Segment Insights ### By Application: Preventive Vaccines (Largest) vs. Therapeutic Vaccines (Fastest-Growing) The Human Vaccines Market is predominantly led by [Preventive Vaccines](https://www.marketresearchfuture.com/reports/preventive-vaccine-market-43345), which account for a significant share due to their extensive application in eradicating infectious diseases. These vaccines are crucial for public health initiatives and have widespread acceptance, thereby dominating market distribution. [Therapeutic Vaccines](https://www.marketresearchfuture.com/reports/therapeutic-vaccines-market-42601), while smaller in market share, are witnessing rapid growth as they focus on treating existing health conditions, such as cancers and autoimmune diseases, which expands their relevance in the healthcare sector. Preventive Vaccines (Dominant) vs. Therapeutic Vaccines (Emerging) Preventive Vaccines represent the cornerstone of the Human Vaccines Market, characterized by their focus on prevention through immunization against infectious diseases. Their established nature and strong public health mandates make them the most significant segment. On the other hand, Therapeutic Vaccines are emerging as a transformative segment, aimed at treating diseases rather than preventing them. With advancements in biopharmaceuticals, these vaccines are gaining traction, particularly in cancer therapy. This diversification allows for a broader range of treatment options, thereby boosting interest and investment in research and development within this dynamic field. ### By Type: Live Attenuated Vaccines (Largest) vs. mRNA Vaccines (Fastest-Growing) The human vaccines market is currently dominated by live attenuated vaccines, which hold the largest share due to their proven efficacy and long-term immunity benefits. Inactivated vaccines also have a significant presence, but live attenuated vaccines surpass them in market penetration. Subunit vaccines, while effective, occupy a smaller slice of the market, as do mRNA vaccines, which are gaining traction due to their groundbreaking approach to infection prevention. Live Attenuated Vaccines (Dominant) vs. mRNA Vaccines (Emerging) Live attenuated vaccines represent a traditional yet powerful category, often delivering robust immune responses through weakened forms of pathogens. Their efficacy in long-lasting immunity makes them the go-to choice for diseases like measles and mumps. In contrast, mRNA vaccines, although newer, are rapidly becoming a significant player; their quick development and adaptability have positioned them at the forefront, especially highlighted during global health crises like the COVID-19 pandemic. As research continues, the versatility and rapid production timeline of mRNA vaccines indicate their potential for future dominance in the market. ### By Route of Administration: Intramuscular (Largest) vs. Subcutaneous (Fastest-Growing) The Human Vaccines Market exhibits a diverse distribution across the various routes of administration. Intramuscular vaccinations continue to hold the largest share in the market due to their effectiveness and widespread acceptance among healthcare providers. Subcutaneous administration is also significant, yet its growing adoption highlights a notable trend in the market. Oral and intranasal routes are less common but are gradually gaining traction in specific vaccine applications, catering to patient preferences and enhancing compliance. Intramuscular (Dominant) vs. Subcutaneous (Emerging) Intramuscular administration of vaccines remains the dominant method in the Human Vaccines Market, known for its robust immune response and reliable delivery mechanisms. This route allows for deeper tissue penetration, which is crucial for vaccines that require strong systemic effects. In contrast, subcutaneous administration is emerging as a key player due to its advantages in patient comfort and potential for self-administration, appealing to populations that prioritize ease and accessibility. As innovations in formulations and devices continue, subcutaneous vaccines are expected to occupy a more substantial market share, particularly in pediatric and adult immunization campaigns. ### By Target Disease: Viral Infections (Largest) vs. Cancer (Fastest-Growing) In the Human Vaccines Market, the segment distribution reveals viral infections as the dominant shareholder, primarily due to the high prevalence of diseases like influenza and hepatitis. Bacterial infections also hold a significant portion, with vaccines for diseases such as pneumococcal and meningococcal contributing to the market’s stability. Parasitic infections, although critical, represent a smaller fraction, while cancer vaccines are gaining traction, reflecting a dynamic shift in focus towards immunotherapeutic strategies. Viral Infections (Dominant) vs. Cancer (Emerging) Viral infections dominate the Human Vaccines Market largely because they address widespread and challenging infectious diseases like influenza and HPV. Established vaccines in this category maintain a strong market position due to continuous immunization programs and public health initiatives. Conversely, cancer vaccines are emerging strongly, driven by advancements in biotechnology and personalized medicine. This segment is characterized by innovative therapies that harness the immune system to combat various cancers, indicating a shift towards prophylactic and therapeutic vaccines. As research and development intensify in the oncology sector, the popularity and market share of cancer vaccines are expected to see exponential growth. ### By End User: Hospitals (Largest) vs. Clinics (Fastest-Growing) In the Human Vaccines Market, the distribution of market share among end users reveals Hospitals as the leading segment. They account for a significant portion of vaccine administration due to their established infrastructure and access to a large patient base. Clinics follow as a crucial segment, experiencing rapid growth as they shift toward more personalized care approaches. The convenience and accessibility offered by clinics are enhancing their role in the vaccination ecosystem, making them integral to future market dynamics. Hospitals (Dominant) vs. Clinics (Emerging) Hospitals represent the dominant end user segment in the Human Vaccines Market, primarily due to their comprehensive healthcare services and capacity to handle large patient volumes, particularly in urban areas. They are equipped with extensive facilities for vaccination, including specialized staff and technology, which helps in efficient vaccine distribution. On the other hand, Clinics are emerging as vital contributors to the market. They are adapting swiftly to changing healthcare demands, focusing on patient-centric approaches and community outreach. Their growth is driven by increased public awareness of vaccination benefits and a greater emphasis on preventive healthcare within local communities. ## Regional Market Share Analysis ### North America : Market Leader in Vaccines North America continues to lead the Human Vaccines Market, holding a significant share of 400.0M in 2024. The region's growth is driven by advanced healthcare infrastructure, high R&D investments, and a robust regulatory framework that supports vaccine development and distribution. Increasing vaccination rates and public health initiatives further bolster demand, ensuring a steady market expansion. The competitive landscape is characterized by major players such as Pfizer, Moderna, and Johnson & Johnson, which dominate the market with innovative vaccine solutions. The U.S. remains the largest contributor, supported by favorable government policies and funding for [vaccine research](https://www.marketresearchfuture.com/reports/vaccine-research-market-27935). This environment fosters collaboration between public and private sectors, enhancing the region's position as a global leader in vaccine production and distribution. ### Europe : Emerging Vaccine Innovation Hub Europe's Human Vaccines Market is projected to reach 180.0M by 2025, driven by increasing healthcare investments and a strong focus on vaccine innovation. Regulatory bodies like the European Medicines Agency (EMA) play a crucial role in facilitating the approval of new vaccines, ensuring safety and efficacy. The region's commitment to public health initiatives and vaccination campaigns further enhances market demand, particularly in response to emerging infectious diseases. Leading countries such as Germany, France, and the UK are at the forefront of vaccine development, hosting major pharmaceutical companies like Sanofi and GlaxoSmithKline. The competitive landscape is marked by collaborations between governments and private entities, fostering innovation and ensuring a diverse vaccine portfolio. As Europe continues to prioritize health security, the market is expected to grow steadily, supported by regulatory advancements and public health strategies. ### Asia-Pacific : Rapidly Growing Vaccine Market The Asia-Pacific region is witnessing a significant surge in the Human Vaccines Market, projected to reach 70.0M by 2025. This growth is fueled by increasing healthcare expenditures, rising awareness of vaccination benefits, and government initiatives aimed at improving public health. Countries are focusing on expanding their immunization programs, which is critical in combating infectious diseases and enhancing overall health outcomes. Key players in this region include major pharmaceutical companies like Merck & Co. and AstraZeneca, which are actively involved in vaccine development and distribution. Countries such as China and India are leading the charge, supported by favorable regulatory environments and growing investments in healthcare infrastructure. The competitive landscape is evolving, with local manufacturers also emerging to meet the increasing demand for vaccines, ensuring a diverse market offering. ### Middle East and Africa : Emerging Market with Challenges The Middle East and Africa (MEA) region is gradually developing its Human Vaccines Market, projected to reach 16.04M by 2025. The growth is driven by increasing healthcare investments and a rising awareness of vaccination importance. However, challenges such as limited access to healthcare and varying regulatory frameworks across countries can hinder market expansion. Governments are working to improve vaccination rates, which is essential for public health and disease prevention. Countries like South Africa and the UAE are leading the market, with efforts to enhance vaccine accessibility and affordability. The presence of key players such as Novartis and Bayer is crucial in addressing local health needs. Collaborative efforts between governments and international organizations are vital for overcoming barriers and ensuring that vaccines reach underserved populations, paving the way for a more robust market in the future. ## Competitive Benchmarking The Human Vaccines Market is characterized by a dynamic competitive landscape, driven by innovation, strategic partnerships, and a focus on addressing emerging health threats. Key players such as Pfizer (US), Moderna (US), and Johnson & Johnson (US) are at the forefront, leveraging their extensive research capabilities and established market presence to enhance their operational focus. Pfizer (US) has been particularly aggressive in expanding its vaccine portfolio through collaborations and acquisitions, while Moderna (US) emphasizes mRNA technology to develop next-generation vaccines. Johnson & Johnson (US) continues to prioritize global access and affordability, which shapes its strategic positioning in various regions.The market structure appears moderately fragmented, with several players vying for market share. Key business tactics include localizing manufacturing to reduce costs and optimize supply chains, which is crucial in maintaining competitive pricing and ensuring timely delivery. The collective influence of these major companies fosters a competitive environment where innovation and operational efficiency are paramount. In November Pfizer (US) announced a strategic partnership with a leading biotechnology firm to co-develop a novel vaccine targeting emerging viral strains. This collaboration is expected to enhance Pfizer's research capabilities and accelerate the development timeline, reflecting a broader trend of companies seeking synergies to bolster their R&D efforts. Such partnerships may significantly impact market dynamics by enabling faster responses to public health challenges. In October Moderna (US) unveiled plans to expand its manufacturing facilities in Europe, aiming to increase production capacity for its mRNA vaccines. This move is strategically important as it positions Moderna to better serve the European market and respond to potential surges in vaccine demand. The expansion underscores the company's commitment to scaling operations and enhancing supply chain resilience, which is increasingly vital in the current market. In September Johnson & Johnson (US) launched a new initiative focused on equitable vaccine distribution in low-income countries. This initiative not only aligns with global health goals but also enhances the company's reputation and market presence in regions where access to vaccines is limited. By prioritizing social responsibility, Johnson & Johnson is likely to strengthen its competitive edge and foster long-term loyalty among healthcare providers and governments. As of December current trends in the Human Vaccines Market indicate a shift towards digitalization, sustainability, and the integration of AI technologies in vaccine development and distribution. Strategic alliances are increasingly shaping the competitive landscape, allowing companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve, with a greater emphasis on innovation and technology rather than solely on price. Companies that can reliably deliver high-quality vaccines while embracing sustainable practices are likely to emerge as leaders in this rapidly changing market. ## Recent News & Developments Recent developments in the Global Human Vaccines Market have been significantly influenced by various factors, including the ongoing response to infectious diseases and advancements in vaccine technology. In October 2023, Pfizer announced a collaboration with Moderna to enhance mRNA vaccine production efficiency, reflecting an industry trend toward partnerships for rapid vaccine development. Meanwhile, Merck and Co confirmed their investment in next-generation vaccine platforms to combat emerging pathogens, showcasing a commitment to innovation in vaccine efficacy and safety. Currently, companies like Gilead Sciences and Johnson and Johnson are focusing on expanding their pipeline, especially in therapeutic vaccines targeting HIV and cancer, while Roche and Novartis are investing in biopharmaceuticals to enhance immunogenicity. Notably, GlaxoSmithKline has reported a substantial increase in vaccine sales, attributing this to rising vaccination rates globally. In the past two to three years, the market has seen significant growth due to increased vaccination campaigns, particularly against COVID-19, with AstraZeneca and Sanofi making strides in vaccine distribution. The combined efforts of these leading firms illustrate a dynamic landscape in the Global Human Vaccines Market, emphasizing innovation and strategic collaborations to address public health challenges. ## Report Scope | MARKET SIZE 2024 | 666.04(USD Million) | | --- | --- | | MARKET SIZE 2025 | 704.14(USD Million) | | MARKET SIZE 2035 | 1228.11(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.72% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Pfizer (US), Moderna (US), Johnson & Johnson (US), Sanofi (FR), GlaxoSmithKline (GB), Merck & Co. (US), AstraZeneca (GB), Novartis (CH), Bayer (DE) | | Segments Covered | Application, Technology, Route of Administration, Target Disease, End User | | Key Market Opportunities | Advancements in mRNA technology enhance vaccine development speed and efficacy in the Human Vaccines Market. | | Key Market Dynamics | Rising demand for innovative vaccines drives competitive forces and regulatory adaptations in the Human Vaccines Market. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the current valuation of the Human Vaccines Market as of 2024?** A: The Human Vaccines Market was valued at 666.04 USD Million in 2024. **Q: What is the projected market valuation for the Human Vaccines Market in 2035?** A: The market is projected to reach a valuation of 1228.11 USD Million by 2035. **Q: What is the expected CAGR for the Human Vaccines Market during the forecast period 2025 - 2035?** A: The expected CAGR for the Human Vaccines Market during the forecast period 2025 - 2035 is 5.72%. **Q: Which companies are considered key players in the Human Vaccines Market?** A: Key players in the market include Pfizer, Moderna, Johnson & Johnson, Sanofi, GlaxoSmithKline, Merck & Co., AstraZeneca, Novartis, and Bayer. **Q: What are the main segments of the Human Vaccines Market by application?** A: The main segments by application include Preventive Vaccines, Therapeutic Vaccines, Travel Vaccines, and Pediatric Vaccines. **Q: How do the valuations of Preventive and Therapeutic Vaccines compare?** A: Preventive Vaccines are valued between 300.0 and 600.0 USD Million, whereas Therapeutic Vaccines are valued between 150.0 and 300.0 USD Million. **Q: What types of vaccines are included in the Human Vaccines Market?** A: The market includes Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, and mRNA Vaccines. **Q: What is the valuation range for mRNA Vaccines in the market?** A: mRNA Vaccines are valued between 216.04 and 328.11 USD Million. **Q: Which routes of administration are prevalent in the Human Vaccines Market?** A: The prevalent routes of administration include Intramuscular, Subcutaneous, Oral, and Intranasal. **Q: What are the target diseases addressed by the Human Vaccines Market?** A: The market addresses Viral Infections, Bacterial Infections, Parasitic Infections, and Cancer. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/human-vaccines-market-2671*